Bladder Cancer: Treatment in the Metastatic Setting

Opinion
Video

Focusing on the metastatic setting, the expert panel discusses advanced kidney cancer treatment practices, highlighting recent data that are informing treatment decisions.

Recent Videos
Karine Tawagi, MD, and Sia Daneshmand, MD, with the Oncology Brothers presenting slides
Karine Tawagi, MD, and Sia Daneshmand, MD, with the Oncology Brothers presenting slides
Karine Tawagi, MD, and Sia Daneshmand, MD, with the Oncology Brothers presenting slides
Scott T. Tagawa, MD, MS, FACP, FASCO, discusses the recent approval of nivolumab plus chemotherapy for patients with unresectable or metastatic urothelial carcinoma.
Considering cystectomy in patients with bladder cancer may help with managing the shortage of Bacillus Calmette-Guerin, according to Joshua J. Meeks, MD, PhD, BS.
Patients with locally advanced or metastatic urothelial cancer and visceral disease may particularly benefit from enfortumab vedotin plus pembrolizumab, according to Amanda Nizam, MD.
Cretostimogene grenadenorepvec’s efficacy compares favorably with the current nonsurgical standards of care in high-risk, Bacillus Calmette Guerin–unresponsive non-muscle invasive bladder cancer.
Experts on bladder cancer
Related Content
TAS-200 plus cetrelimab did not yield significant results vs chemoradiation in muscle-invasive bladder cancer.

TAS-200 Study in Muscle-Invasive Bladder Cancer Discontinued

Ariana Pelosci
October 9th 2024
Article

TAS-200 plus cetrelimab did not yield significant results vs chemoradiation in muscle-invasive bladder cancer.

Jun Gong, MD, spoke with CancerNetwork® about the latest research from the journal ONCOLOGY® on elderly patients with muscle-invasive bladder cancer.

Oncology Peer Review On-The-Go: Neoadjuvant Chemotherapy for Elderly Patients with Muscle-Invasive Bladder Cancer

Matthew Fowler;Jun Gong, MD
March 15th 2022
Podcast

Jun Gong, MD, spoke with CancerNetwork® about the latest research from the journal ONCOLOGY® on elderly patients with muscle-invasive bladder cancer.

Data from the SunRISe-4 trial demonstrate the benefit of adding TAR-200 to checkpoint inhibition among patients with muscle-invasive bladder cancer.

Neoadjuvant TAR-200 Combo Shows Responses in Muscle-Invasive Bladder Cancer

Kristi Rosa
September 17th 2024
Article

Data from the SunRISe-4 trial demonstrate the benefit of adding TAR-200 to checkpoint inhibition among patients with muscle-invasive bladder cancer.

Emerging Immunotherapy Approaches For Urothelial Cancer

Emerging Immunotherapy Approaches For Urothelial Cancer

Petros Grivas, MD, PhD
February 4th 2019
Podcast

Cancer Network spoke with Dr. Petros Grivas about emerging immunotherapy approaches for the treatment of advanced urothelial cancer.

Durvalumab improved efficacy in patients with muscle-invasive bladder cancer.

Durvalumab Shows Improvement in EFS/OS for Muscle-Invasive Bladder Cancer

Roman Fabbricatore
June 25th 2024
Article

Durvalumab improved efficacy in patients with muscle-invasive bladder cancer.

UGN-102 Shows Durable 1-Year Responses in Low-Grade, Intermediate-Risk NMIBC

UGN-102 Shows Durable 1-Year Responses in Low-Grade, Intermediate-Risk NMIBC

Roman Fabbricatore
June 17th 2024
Article

UGN-102 also demonstrated a 79.6% complete response rate at 3 months in the phase 3 ENVISION trial.